Needham & Company
-
Jazz Pharmaceuticals (JAZZ) PT Lowered to $205 at Needham
-
Needham & Company Reiterates Jazz Pharmaceuticals (JAZZ) at Buy Following Sunosi Deal, Sees it as a Positive
-
Needham & Company Reiterates Jazz Pharmaceuticals (JAZZ) at Buy on Earnings, Analyst Doesn't Expect Stock to Uptick Short-Term, but Highlights Strong Execution and Fundamentals
-
Bicycle Therapeutics Plc (BCYC), Jazz Pharmaceuticals (JAZZ) and SAGE Therapeutics (SAGE) - Needham's Favorite 2022 Biotech Picks
-
Jazz Pharmaceuticals (JAZZ) Remains Undervalued, but Epidiolex Sales Growth Rate Will Continue Slowing Down - Needham
-
Needham & Company Starts Jazz Pharmaceuticals (JAZZ) at Buy
-
Pre-Open Stock Movers 2/25: (BNFT) (SSF) (SFXE) Higher; (SLCA) (LC) (SAM) (HPQ) Lower (more...)
-
Streetinsider.com's Hot Lunchtime Reads 01/02: (NBS) (KNDI) (FIO) (MSFT)
-
StreetInsider.com Pre-Open Movers 03/05: (ZOLT) (APP) (MTG) Higher; (IPXL) (JCP) (FR) Lower (more...)
-
Notable 52-Week Highs and Lows of the Day 11/05: ATML, FLR, SBUX, JAZZ High; AIB/IRE, CO, PESI Low
-
Notable Analyst Rating Changes 06/15: FINL, JAZZ, AMKR, JCI Upgraded; SMBL, NFLX, ELY, ROSE Downgraded
-
Unusual 11 Mid-Day Movers 9/4: TONE, JAZZ, LTXC, ESL Higher; ARRY, BPI, ZQK, GIII Lower

